Center-Authored Papers

Filters: Author is Paietta, Elisabeth  [Clear All Filters]
2016
Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen I-M, Pei D, Iacobucci I, Valentine M, Pounds SB et al..  2016.  High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2016690073. Abstract
Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I et al..  2016.  Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.. Nature communications. 7:13331. Abstract
2015
Cesano A, Willman CL, Kopecky KJ, Gayko U, Putta S, Louie B, Westfall M, Purvis N, Spellmeyer DC, Marimpietri C et al..  2015.  Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia.. PloS one. 10(4):e0118485. Abstract
2014
Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA et al..  2014.  Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.. British journal of haematology. 164(2):223-32. Abstract
Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK et al..  2014.  Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.. British journal of haematology. Abstract
2013
Poiré X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA et al..  2013.  Arsenic Trioxide in Front-line Therapy of Acute Promyelocytic Leukemia (C9710): Prognostic Significance of FLT3 Mutations and Complex Karyotype.. Leukemia & lymphoma. Abstract
Douer D, Zickl LN, Schiffer CA, Appelbaum FR, Feusner JH, Shepherd L, Willman CL, Bloomfield CD, Paietta E, Gallagher RE et al..  2013.  All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129.. Leukemia research. Abstract
2012
Wiernik PH, Sun Z, Gundacker H, Dewald G, Slovak ML, Paietta E, Kim HT, Appelbaum FR, Cassileth PA, Tallman MS.  2012.  Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17).. Medical oncology (Northwood, London, England). 29(3):2095-101. Abstract
Gallagher RE, Moser BK, Racevskis J, Poiré X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou D-C et al..  2012.  Treatment-influenced associations of PML-RARα mutations, FLT3 mutations and additional chromosome abnormalities in relapse acute promyelocytic leukemia.. Blood. Abstract
Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P et al..  2012.  A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chromic myeloid leukemia.. Blood. Abstract
2010
Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH et al..  2010.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 116(25):5650-9. Abstract